NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
企業コードNGEN
会社名NervGen Pharma Corp
上場日Mar 13, 2019
最高経営責任者「CEO」Rogers (Adam H)
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地Suite 1703 - 595 Burrard Street
都市VANCOUVER
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号V7X 1J1
電話番号16047225361
ウェブサイトhttps://www.nervgen.com/
企業コードNGEN
上場日Mar 13, 2019
最高経営責任者「CEO」Rogers (Adam H)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし